Pelican-Cancer-Foundation-logos
Donate Now
Search
Pelican-Cancer-Foundation-logos

Dedicated to helping patients with bowel and liver cancer live well for longer

Donate Now
Search
  • Home
  • About us
    • About us
    • What we do
      • Our achievements
      • The Future
    • Who we are
      • Trustees
      • Our Team
      • Patrons
      • Annual Accounts
    • Partnerships
    • Vacancies
    • News
  • Education
    • Pelican OReCO
      • OReCO On-line Resources
      • OReCO Partners & Sponsors
      • Pelican OReCO Workshops
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
    • LARS
    • Sponsors
      • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Films
  • Research
    • MERCURY 3
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Previous Research Areas
      • Prostate Cancer Research
        • Prostate cancer
        • Focal therapy and HIFU research
        • MRI research for prostate cancer
        • Prostate cancer colloquiums
        • FORECAST
        • Trachtomap
        • Papers of interest
      • Bladder cancer research
        • Bladder cancer
        • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for research applicants
      • Peer Review Panel Terms of Reference
      • Research Review Panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Pseudomyxoma peritonei
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Shares
      • In memory
    • Fundraise for us
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
    • Leave a Gift in your Will
    • Become a Corporate Partner
    • Trusts, Foundations & Philanthropy
    • Tell us your story
  • Contact us

Key papers – IMPACT

March 14, 2018 by pelicanadmin

Colorectal Liver Metastases

Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Folprecht G, Van Cutsem E, Ducreux M, Nordlinger B; European Organisation for Research and Treatment of Cancer (EORTC); Gastro-Intestinal Tract Cancer Group; Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG).

RE: Local Treatment of Unresectable Colorectal Liver Metastases: Results of a RandomizedPhase II Trial. Macbeth F, Farewell V, Treasure T.

Progress and future direction in the management of advanced colorectal cancer G. M. Brown, M. J. Solomon First published: 13 April 2018

NICE Colorectal Cancer Quality Standard 20 [QS20], published August 2012

NICE guidance – Colorectal cancer: diagnosis and management (CG131), Last updated December 2014

Randomised multicentre trial of gadoxetic acid-enhanced MRI vs conventional MRI or CT in the staging of colorectal liver metastases, Zech CJ et al. British Journal of Surgery 2014, 101:613-21

Chemotherapy before liver resection of colorectal metastases – friend or foe? Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA. Annals of Surgery 2012, 255(2): 237-47.

One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach. Hamady ZZ, Lodge JP, Welsh FK, Toogood GJ, White A, John TG,. Rees M. Annals of Surgery 2014; 259(3):543-8.

Patient-reported outcomes after hepatic resection of colorectal liver metastases. Rees JR, Blazeby JM, Fayers P, Friend EA, Welsh FK, John TG, Rees M. J Clinical Oncology 2012; 30(12):1364-70.

Stereotactic body radiotherapy for liver metastases. Aitken KL, Hawkins MA, Clin Oncol (R Coll Radiol) 2015, 27(5):307-15

Impact of hepatobiliary service centralization on treatment and outcomes in patients with colorectal cancer and liver metastases  E. Vallance  J. vanderMeulen  A. Kuryba  I. D. Botterill  J. Hill  D. G. Jayne  K. Walker

First published: 2 March 2017 https://doi.org/10.1002/bjs.10501

Cited by: 2 https://onlinelibrary.wiley.com/doi/full/10.1002/bjs.10501


Colorectal Lung Metastases

Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566patients with 1037 metastases. de Baère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, Fonck M, Escudier B, Palussiére J.

Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung metastases. de Baère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, Fonck M, Escudier B, Palussiére J.

Systematic review and meta-analysis – Gonzalez et al., Annals of Surgical Oncology 2013;20:572-9
2925 patients 25 studies, 27%-68% OS 5 years.

Pasturino U, Buyse M, Friedel G, et al., Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997 Jan;113(1):37-49.

Gonzalez M, Poncet A Combescure C et al., Risk Factors for survival after lung metastasectomy in colorectal cancer patients: systematic review and meta-analysis.  Ann Surg Oncol. 2013 Feb;20(2):572-9.

Surgery and ablative techniques for lung metastases in the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) trial: is there equivalence? Treasure T et a., J Thorac Dis. 2016.

Prognostic factors after pulmonary metastasectomy of colorectal cancers: a single centre experience. Fournel L et al. J Thorac Dis. 2017.

Pulmonary metastasectomy: an overview Petrella F et al., J Thorac Dis 2017.

 


Pathology

Molecular testing key papers:

https://www.nice.org.uk/guidance/dg27

Molecular testing in advanced/metastatic disease

RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group

Newton ACS Wong1, David Gonzalez2, Manuel Salto-Tellez3, Rachel Butler4, Salvador J Diaz-Cano5, Mohammad Ilyas6, William Newman7, Emily Shaw8, Philippe Taniere9, Shaun V Walsh10

Standards for integrated reporting in cellular pathology January 2017

Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Richman SD1, Chambers P, Seymour MT, Daly C, Grant S, Hemmings G, Quirke P.

Annual Report of the Chief Medical Officers 2016


Colorectal Peritoneal Metastases

Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. Verwaal VJ1, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA.

Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. Elias D1, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O.

Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone R Mirnezami, A M Mehta, K Chandrakumaran, T Cecil, B J Moran, N Carr, V J Verwaal, F Mohamed & A H Mirnezami

Peritoneal metastases of lower GI tract origin… Ung L:  J Cancer Res Clin Oncol 2013; 139:1899-1908

Peritoneal carcinomatosis of colorectal cancer… Massalou D: American Journal of Surgery 2017; 213:377-87

External validation of models predicting the individual risk of metachronous peritoneal carcinomatosis from colon and rectal cancer. Segelman J: Colorectal Dis 2015; 18:378-85.

NICE guidance IPG 331 Cytoreduction surgery followed by hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis Feb 2010

NHS Commissioning A08/P/a  Cytoreduction surgery for patients with peritoneal carcinomatosis April 3013

Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. Rahul Rajeev, Brittany Klooster, and Kiran K. Turag J Gastrointest Oncol. 2016 Feb; 7(1): 122–128

A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin. Cao C, Yan TD, Black D, Morris DL. Ann Surg Oncol. 2009 Aug 12;16(8):2152–65

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al.  Lancet Oncol. 2016;17(12):1709–19


Local Recurrence

Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P.  Ann Surg. 2011 May;253(5):890-9.

Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. PelvEx Collaborators (83)

Anastomotic Leaks After Restorative Resections for Rectal Cancer Compromise Cancer Outcomes and Survival. Lu ZR, Rajendran N, Lynch AC, Heriot AG, Warrier SK. Dis Colon Rectum. 2016 Mar;59(3):236-44.

Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg. 2013 Jul;100(8):1009-14.

Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg. 2013 Jul;100(8):E1-33.


Other papers collected by Pelican

The Fundamental Difference Between Cancer Treatment and Patient Care

Advances in surgical management for locally recurrent rectal cancer: How far have we come? Daniel Jin-Keat Lee, Peter M Sagar, Gaitri Sadadcharam, and Kok-Yang Tan
World J Gastroenterol. 2017 Jun 21; 23(23): 4170–4180.

Effect of specialist decision-making on treatment strategies for colorectal liver metastases Jones RP1, Vauthey JN, Adam R, Rees M, Berry D, Jackson R, Grimes N, Fenwick SW, Poston GJ, Malik HZ.  Br J Surg. 2012 Nov;99(11):1605

Large variation in the utilization of liver resections in stage IV colorectal cancer patients with metastases confined to the liver AlibR.H.A.VerhoevencR.M.H. Roumend V.E.P.P. LemmenscA.M.Rijkenb, J.H.W.De Wilta

European Journal of Surgical Oncology (EJSO) Volume 41, Issue 9, September 2015, Pages 1217-1225

Regional and inter-hospital differences in the utilisation of liver surgery for patients with synchronous colorectal liver metastases in the Netherlands Lam-BoeraE.P. van der StokbJ. HuiskenscR.H.A., VerhoevendC.J.A., PunteM.A.G.,  ElferinkdJ.H, de WiltaC.Verhoefb

the CAIRO5/CHARISMA Group1
European Journal of Cancer Volume 71, January 2017, Pages 109-116

Treatment of colorectal peritoneal metastases requires multidisciplinary efforts Diane Goéré, Maximiliano Gelli

Lancet Oncology  Volume 17, No. 12, p1630–1631, December 2016


Onco-Surgical Management of Liver Metastases from Colorectal Cancer

Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway J.-H. Angelsen, A. Horn,  Sorbye,  G. E. Eide, I. M. Løes, A. Viste
BJS First published: 9 February 2017 DOI: 10.1002/bjs.10457

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: from novelty to routine in selected cases – B Moran.
Techniques in Coloproctology. September 2017, Volume 21, Issue 9, pp 767–769 | Cite as

 

 

 

 

Filed Under: Uncategorized

Stay in touch

Sign up to hear from us
Donate Now

© 2023 Pelican Cancer Foundation - all rights reserved

  Registered Charity Number: 1141911 -  Privacy Policy